-
公开(公告)号：US09758487B2
公开(公告)日：2017-09-12
申请号：US15194980
申请日：2016-06-28
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Carol Bachand , Makonen Belema , Daniel H. Deon , Andrew C. Good , Jason Goodrich , Clint A. James , Rico Lavoie , Omar D. Lopez , Alain Martel , Nicholas A. Meanwell , Van N. Nguyen , Jeffrey Lee Romine , Edward H. Ruediger , Lawrence B. Snyder , Denis R. St. Laurent , Fukang Yang , David R. Langley , Gan Wang , Lawrence G. Hamann
IPC: A61K38/20 , A61K31/4164 , A61K31/517 , A61K31/715 , A61K38/46 , A61P31/00 , C07D403/02 , C07D401/00 , C07D233/64 , C07D401/14 , C07D403/14 , A61K31/4178 , A61K45/06 , C07D405/14 , C07D413/14 , C07D409/14 , C07D417/14
CPC classification number: C07D233/64 , A61K31/4178 , A61K45/06 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07F5/025 , C07F7/0812
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
-
公开(公告)号：US08642025B2
公开(公告)日：2014-02-04
申请号：US13650374
申请日：2012-10-12
Applicant: Bristol-Myers Squibb Company
Inventor： Carol Bachand , Makonen Belema , Daniel H. Deon , Andrew C. Good , Jason Goodrich , Clint A. James , Rico Lavoie , Omar D. Lopez , Alain Martel , Nicholas A. Meanwell , Van N. Nguyen , Jeffrey Lee Romine , Edward H. Ruediger , Lawrence B. Snyder , Denis R. St. Laurent , Fukang Yang , David R. Langley , Lawrence G. Hamann
IPC: A61K31/454 , A61K31/713 , A61K31/4178 , A61K31/5377 , A61K31/496 , A61K31/7056 , A61K38/05 , A61K38/21 , A61K38/20 , A61P31/14 , C07D413/14 , C07D401/14 , C07D403/14
CPC classification number: C07D233/64 , A61K31/4178 , A61K45/06 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07F5/025 , C07F7/0812
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Abstract translation: 本公开涉及用于治疗丙型肝炎病毒（HCV）感染的化合物，组合物和方法。 还公开了含有这些化合物的药物组合物和使用这些化合物治疗HCV感染的方法。
-
公开(公告)号：US20130280211A1
公开(公告)日：2013-10-24
申请号：US13919027
申请日：2013-06-17
Applicant: Bristol-Myers Squibb Company
Inventor： Carol Bachand , Makonen Belema , Daniel H. Deon , Andrew C. Good , Jason Goodrich , Clint A. James , Rico Lavoie , Omar D. Lopez , Alain Martel , Nicholas A. Meanwell , Van N. Nguyen , Jeffrey Lee Romine , Edward H. Ruediger , Lawrence B. Snyder , Denis R. ST. Laurent , Fukang Yang , David R. Langley , Lawrence G. Hamann
IPC: C07D403/14 , C07D401/14 , A61K45/06 , A61K31/5377 , C07F7/10 , A61K31/695 , A61K31/4178 , A61K31/4545
CPC classification number: C07D403/14 , A61K31/4178 , A61K31/4545 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D401/14 , C07F7/10
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
-
4.发明授权Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation 有权咪唑并噻二唑和咪唑并哒嗪衍生物作为治疗血小板聚集的蛋白酶活化受体4（PAR4）抑制剂公开(公告)号：US09518064B2
公开(公告)日：2016-12-13
申请号：US14396831
申请日：2013-04-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal
Inventor： Alain Martel , François Tremblay , Anne Marinier , Eldon Scott Priestley , Shoshana L. Posy , R. Michael Lawrence , Michael M. Miller
IPC: C07D513/04 , C07D487/04 , A61K38/12 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/497 , A61K31/506 , A61K31/513 , A61K31/5377
CPC classification number: C07D513/04 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/497 , A61K31/506 , A61K31/513 , A61K31/5377 , A61K38/12 , C07D487/04
Abstract: The present invention provides imidazothiadiazole compounds of Formula (I); Wherein W, Y, R0, R2, R4, Ra, Rb, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
公开(公告)号：US09227961B2
公开(公告)日：2016-01-05
申请号：US14488990
申请日：2014-09-17
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Carol Bachand , Makonen Belema , Daniel H. Deon , Andrew C. Good , Jason Goodrich , Clint A. James , Rico Lavoie , Omar D. Lopez , Alain Martel , Nicholas A. Meanwell , Van N. Nguyen , Jeffrey Lee Romine , Edward H. Ruediger , Lawrence B. Snyder , Denis R. St. Laurent , Fukang Yang , David R. Langley , Lawrence G. Hamann
IPC: C07D401/14 , C07D403/14 , C07D413/14 , C07D233/64 , C07D405/14 , A61K31/4178 , A61K45/06
CPC classification number: C07D233/64 , A61K31/4178 , A61K45/06 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07F5/025 , C07F7/0812
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
-
Patent Agency Ranking
6.发明申请IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION 有权作为用于治疗细胞聚集的蛋白激活受体4（PAR4）抑制剂的咪唑唑二酮衍生物公开(公告)号：US20150133446A1
公开(公告)日：2015-05-14
申请号：US14396807
申请日：2013-04-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal
Inventor： R. Michael Lawrence , Michael M. Miller , Dietmar Alfred Seiffert , Shoshana L. Posy , Pancras C. Wong , Jacques Banville , Edward H. Ruediger , Daniel H. Deon , Alain Martel , François Tremblay , Julia Guy , Jean-François Lavallée , Marc Gagnon
IPC: C07D513/04 , A61K31/506 , A61K31/5377 , A61K31/4355 , A61K31/433 , A61K31/4439
CPC classification number: C07D513/04 , A61K31/433 , A61K31/4355 , A61K31/4439 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D519/00
Abstract: The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, Rx, R1, R2, R3, X1, X2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments.
Abstract translation: 本发明提供式（I）的咪唑并噻二唑化合物，其中A，B，D，Rx，R1，R2，R3，X1，X2和s如本文所定义，或其立体异构体，互变异构体，药学上可接受的盐或溶剂化物形式， 其中所有变量如本文所定义。 这些化合物是血小板聚集的抑制剂，因此可以用作药物。
-
7.发明申请IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION 有权作为用于治疗血小板聚集的蛋白激活受体4（PAR4）抑制剂的咪唑并噻唑和咪唑吡嗪衍生物公开(公告)号：US20150119390A1
公开(公告)日：2015-04-30
申请号：US14396831
申请日：2013-04-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Monteal
Inventor： Alain Martel , François Tremblay , Anne Marinier , Eldon Scott Priestley , Shoshana L. Posy , R. Michael Lawrence , Michael M. Miller
IPC: C07D513/04 , A61K31/433 , A61K31/5377 , A61K31/513 , A61K31/437 , A61K31/497 , A61K31/506 , A61K31/4439
CPC classification number: C07D513/04 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/497 , A61K31/506 , A61K31/513 , A61K31/5377 , A61K38/12 , C07D487/04
Abstract: The present invention provides imidazothiadiazole compounds of Formula (I); Wherein W, Y, R0, R2, R4, Ra, Rb, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
Abstract translation: 本发明提供式（I）的咪唑并噻二唑化合物; 其中W，Y，R0，R2，R4，Ra，Rb，X1，X2，X3和X4如本文所定义，或其立体异构体，互变异构体，药学上可接受的盐，前药酯或溶剂化物形式，其中所有变量 如本文所定义。 这些化合物是血小板聚集的抑制剂，因此可以用作治疗或预防血栓栓塞障碍的药物。
-
公开(公告)号：US20130034520A1
公开(公告)日：2013-02-07
申请号：US13650374
申请日：2012-10-12
Applicant: Bristol-Myers Squibb Company
Inventor： Carol Bachand , Makonen Belema , Daniel H. Deon , Andrew C. Good , Jason Goodrich , Clint A. James , Rico Lavoie , Omar D. Lopez , Alain Martel , Nicholas A. Meanwell , Van N. Nguyen , Jeffrey Lee Romine , Edward H. Ruediger , Lawrence B. Snyder , Denis R. St. Laurent , Fukang Yang , David R. Langley , Gan Wang , Lawrence G. Hamann
IPC: A61K31/4178 , C07D413/14 , A61K31/5377 , A61K31/496 , C07D401/14 , A61P31/14 , A61K38/05 , A61K38/21 , A61K31/7056 , A61K38/20 , A61K31/713 , C07D403/14 , A61K31/454
CPC classification number: C07D233/64 , A61K31/4178 , A61K45/06 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07F5/025 , C07F7/0812
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
-
公开(公告)号：US09862730B2
公开(公告)日：2018-01-09
申请号：US14396807
申请日：2013-04-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal
Inventor： R. Michael Lawrence , Michael M. Miller , Dietmar Alfred Seiffert , Shoshana L. Posy , Pancras C. Wong , Jacques Banville , Edward H. Ruediger , Daniel H. Deon , Alain Martel , François Tremblay , Julia Guy , Jean-François Lavallée , Marc Gagnon
IPC: C07D513/04 , C07D519/00 , A61K45/06 , A61K31/433 , A61K31/4355 , A61K31/4439 , A61K31/506 , A61K31/5377
CPC classification number: C07D513/04 , A61K31/433 , A61K31/4355 , A61K31/4439 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D519/00
Abstract: The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, Rx, R1, R2, R3, X1, X2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments.
-
公开(公告)号：US08846023B2
公开(公告)日：2014-09-30
申请号：US14021686
申请日：2013-09-09
Applicant: Bristol-Myers Squibb Company
Inventor： Carol Bachand , Makonen Belema , Daniel H. Deon , Andrew C. Good , Jason Goodrich , Clint A. James , Rico Lavoie , Omar D. Lopez , Alain Martel , Nicholas A. Meanwell , Van N. Nguyen , Jeffrey Lee Romine , Edward H. Ruediger , Lawrence B. Snyder , Denis R. St. Laurent , Fukang Yang , David R. Langley , Gan Wang , Lawrence G. Hamann
IPC: C07D403/14 , C07D405/14 , C07D417/14 , A61K31/506 , A61K31/4178 , A61K31/427 , A61K31/13 , A61K31/7105 , A61K31/4745 , A61K31/7056 , A61K38/20 , A61K38/21 , C07D401/14
CPC classification number: A61K31/506 , A61K31/13 , A61K31/4178 , A61K31/427 , A61K31/4745 , A61K31/7056 , A61K31/7105 , A61K38/2013 , A61K38/204 , A61K38/208 , A61K38/21 , A61K38/212 , C07D401/14 , C07D403/14 , C07D405/14 , C07D417/14
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.06 seconds)
